ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

リルゾール

Riluzole

HCID 5070
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1744-22-5
標準SMILES
Nc1nc2ccc(OC(F)(F)F)cc2s1
InChIKey
FTALBRSUTCGOEG-UHFFFAOYSA-N
分子式
C8H5F3N2OS
平均分子量
234.2 g/mol
単同位体質量
234.00746845

概要

Riluzole is a member of benzothiazoles.

名称と識別子

優先名称
Riluzole
IUPAC
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
現地名
リルゾール
英語名
Riluzole
分子式
C8H5F3N2OS
分子量
234.2

名称と別名

riluzole1744-22-5Rilutek2-Amino-6-(trifluoromethoxy)benzothiazole6-(trifluoromethoxy)-1,3-benzothiazol-2-amineRiluzolRiluzolumRP-542742-Benzothiazolamine, 6-(trifluoromethoxy)-Tiglutik2-amino-6-trifluoromethoxybenzothiazoleRP 54274
名称をさらに表示
2-アミノ-6-(トリフルオロメトキシ)ベンゾチアゾールリルゾール2-アミノ-6(トリフルオロメトキシ)ベンゾチアゾール2-アミノ-6(トリフルオロメトキシ)ベンゾチアゾール, 97%リルゾール (JAN)6-(トリフルオロメトキシ)ベンゾチアゾール-2-イルアミンリルテック2-アミノ-6-トリフルオロメトキシベンゾチアゾール6-(トリフルオロメトキシ)ベンゾチアゾール-2-アミン6-(トリフルオロメトキシ)-1,3-ベンゾチアゾール-2-アミン6-(トリフルオロメトキシ)-1,3-ベンゾチアゾール-2-イルアミン6-(Trifluoromethoxy)benzo[d]thiazol-2-amineCBI-BB ZERO/0017856-trifluoromethoxy-2-aminobenzothiazole6-TRIFLUOROMETHOXYBENZOTHIAZOLE-2-YL-AMINEuzoLBF-37NSC8463PK 26124
EXSERVANNSC-753433NSC-7598237LJ087RS6FBENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-BHV-0223PK26124RP54274

データベース識別子

CAS
1744-22-5
PubChem CID
5070
DTXSID
DTXSID3045192
ChEMBL
CHEMBL744
ChEBI
CHEBI:8863
UNII
7LJ087RS6F
EC Number
605-724-6
Nikkaji
J22.921K

物性

構造計算による物性

XLogP
3.6
極性表面積
76.4 Ų
水素結合供与体数
1
水素結合受容体数
7
回転可能結合数
1
重原子数
15
形式電荷
0
複雑度
238

実験および物理化学的性質

Drugs · 3 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Pharmaceuticals -> Nervous system -> Other nervous system drugs

LogP · 2 件

2.3

3.34

Solubility · 2 件

3.95e-02 g/L

22.1 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 5 件

Breast Feeding; Lactation; Excitatory Amino Acid Antagonists; Neuroprotective Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point119 °C
Physical DescriptionSolid

物理化学的性質

融点
116 · 116-118°C
沸点
296.3 · 296.3±50.0 °C(Predicted)
比重(密度)
1.572 · 1.572±0.06 g/cm3(Predicted)
貯蔵温度
2 · 2-8°C
溶解性
25 · DMSO:「25」mg/mL

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (91.9%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 6 notifications to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (91.9%)

毒性情報

TreatmentTreatment should be supportive and directed toward alleviating symptoms. Severe methemoglobinemia may be rapidly reversible after treatment with methylene blue. (L1712)
Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1 件

Serum aminotransferase elevations occur in approximately up to 12% of patients on long term riluzole therapy, but elevations above 3 times the upper limit of normal (ULN) occur in less than 3% of patients. These elevations are usually mild-to-moderate in severity and are rarely associated with symptoms. Most elevations resolve spontaneously, but persistent or marked elevations require drug discontinuation or dose modification. Routine monitoring of serum aminotransferase levels is recommended for the first 6 months of therapy. Clinically apparent liver injury due to riluzole is rare, but several cases have been reported, arising after 1 to 12 months of therapy and characterized by a hepatocellular or mixed pattern of serum enzyme elevations. Immunoallergic and autoimmune features were uncommon. Most cases were mild to moderate in severity and recovery was rapid upon drug discontinuation, but evidently fatal cases have been reported to the sponsor.

化学と産業

薬理情報

ATC Code · 3 件

N07XX02

N - Nervous system

QN - Nervous system

Protein Binding96% bound to plasma proteins, mainly to albumin and lipoprotein over the clinical concentration range.
Pharmacodynamics · 1 件

Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy. It is also neuroprotective in various <i>in vivo</i> experimental models of neuronal injury involving excitotoxic mechanisms. The etiology and pathogenesis of amyotrophic lateral sclerosis (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective.

Mechanism of Action · 1 件

The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Biological Half-LifeThe mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.
Metabolism/Metabolites · 3 件

Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450&ndash;dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans.

Riluzole has known human metabolites that include N-Hydroxyriluzole, 7-hydroxy-riluzole, 4-hydroxy-riluzole, and 5-hydroxy-riluzole.

関連反応

68 件
反応記録を作成
HRID 9568 の反応式
HRID 9568反応物として
HRID 30883 の反応式
HRID 30883反応物として
HRID 118455 の反応式
HRID 118455反応物として
HRID 177030 の反応式
HRID 177030反応物として
HRID 205169 の反応式
HRID 205169反応物として
HRID 256821 の反応式
HRID 256821反応物として
HRID 256824 の反応式
HRID 256824反応物として
HRID 410718 の反応式
HRID 410718反応物として
前へ1 / 9 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
外見
個体
酸解離定数(Pka)
2.96 · 2.96±0.10(Predicted)
色
白い
Merck
14 · 14,8223
安定性
-20 °C · -20°C の DMSO またはエタノール溶液で最大 2 か月間保存できます。
InChI
InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
InChIKey
FTALBRSUTCGOEG-UHFFFAOYSA-N
SMILES
S1C2=CC(OC(F)(F)F)=CC=C2N=C1N

化学的性質

化学的特性White Crystalline Solid

Exposure RoutesRiluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.
Toxicity Summary · 1 件

The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Signs and SymptomsSymptoms include such as nausea and fatigue [Wikipedia].
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Riluzole

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 85 mg/kg (p.o., mice) (L1859) LD50: 34.5 mg/kg (i.v, mice) (L1859) LD50: 45 mg/kg (p.o., rat) (L1859) LD50: 21 mg/kg (i.v, mice) (L1859)

安全データ

wgk
3
rtecs
DL2830000
ridadr
UN 2811 6.1/PG 3
毒性
LD50 in mice (mg/kg): 46 i.p.; 67 orally (Mizoule)
hs_code
2934200090
risk_code
25
hazard_code
T,Xi
hazard_note
Irritant
safety_code
45
hazard_class
6.1
packing_group
II
Hazard Classifications
Acute Tox. 2 Oral
ストレージクラス
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450&ndash;dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans. Half Life: The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.

FDA Pharmacological Classification · 6 件

7LJ087RS6F

RILUZOLE

Established Pharmacologic Class [EPC] - Benzothiazole

Chemical Structure [CS] - Benzothiazoles

Riluzole is a Benzothiazole.

RILUZOLE

MeSH Pharmacological Classification · 3 件

Drugs used to prevent SEIZURES or reduce their severity.

Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and ExcretionRiluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.
Cellular LocationsMembrane

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >100

For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

応用分野 · 2 件

説明Rilutek was launched in Germany, the UK and US (orphan drug status) for treatment of amyotrophic lateral sclerosis (ALS) and is the first drug approved for this indication. A one step synthesis from 4-(trifluoromethoxy)aniline provides a supply of the compound. The source of its neuroprotective and anticonvulsant activity is not clearly understood. It antagonizes excitatory amino acids and blocks presynaptic release of glutamate, is an antagonist of NMDA-induced acetylcholine release and inhibited glutamate and quisqualate induced increases in cGMP but does not bind to NMDA or Kainic receptors. Rilutek has no affinity for glutamate, GABAbenzodiazepine, glycine and adenosine receptors. It easily crosses the blood brain barrier and depresses glutamatergic neurotransmission, stabilizes voltagedependent Na channels in their inactive form and activates G-protein dependent processes.

使用Labeled Riluzole, intended for use as an internal standard for the quantification of Riluzole by GC- or LC-mass spectrometry.

上流・下流製品情報

上流原料

4-(トリフルオロメトキシ)アニリン